By Adriano Marchese
Eli Lilly & Co. said Tuesday that it has launched new doses of its obesity treatment drug and reduced its prices.
The pharmaceutical company said it has launched 7.5 and 10 milligram single dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram as well as 10 and 12.5 milligram vials.
The company has also reduced the price through its Self Pay Journey program. The program reduces the price of the 7.5 mg and 10 mg doses to $499 per month from $599 and $699, respectively, at first fill and refills that occur within 45 days of prior delivery.
Eli Lilly's new price points and offerings are only through its proprietary LillyDirect Self Pay Pharmacy Solutions which the company said "enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance."
Zepbound, a dual receptor agonist obesity medication, reduces appetite and how much the recipient can eat, supporting other weight loss efforts such as reduced calorie diets and physical exercise.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
The pharmaceutical company said it has launched 7.5 and 10 milligram single-dose vials of its Zepbound drug, also known as tirzepatide, which join the existing lineup of 2.5 and 5 milligram vials. "Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points," at 7:21 a.m. incorrectly said Zepbound also comes in 10 and 12.5 milligram vials.
(END) Dow Jones Newswires
February 25, 2025 09:02 ET (14:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。